Infigratinib(Truseltiq)

Infigratinib is a prescription drug targeting FGFR1, FGFR2, and FGFR3. It received accelerated approval from the U.S. FDA in May 2021 and was first launched in the United States. It must be used strictly under medical supervision.

Targets of Action

FGFR1, FGFR2, FGFR3

Dosage and Administration

Route and frequency of Infigratinib administration: Oral, once daily.

Infigratinib dosage should be adjusted according to the patient's actual condition; specific adjustments require consultation with a physician and adherence to medical advice.

Recommended reading: Dosage and Administration of Infigratinib

Side Effects

Common side effects: Nail changes, oral ulcers (mucositis/stomatitis), etc.

Serious side effects: Retinal pigment epithelial detachment, hyperphosphatemia, and soft tissue calcification, etc.

Reference article: Side Effects of Infigratinib

Use in Special Populations

Pregnancy: Effective contraception must be used during treatment and for at least one month after treatment ends.

Lactation: Do not breastfeed during treatment and for one month after the last dose.

Daily Precautions

1. Take Infigratinib at approximately the same time each day.

2. Take Infigratinib capsules on an empty stomach, at least 1 hour before or 2 hours after a meal.

3. Do not consume or drink grapefruit products during treatment.

FDA，2021.05